BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2025 7:38:49 AM | Browse: 226 | Download: 950
Publication Name World Journal of Gastroenterology
Manuscript ID 101672
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Xue Yin, Na Deng, Xiao-Yan Ding, Jing-Long Chen and Wei Sun
ORCID
Author(s) ORCID Number
Jing-Long Chen http://orcid.org/0000-0003-1640-7115
Wei Sun http://orcid.org/0000-0001-7511-529X
Funding Agency and Grant Number
Funding Agency Grant Number
the Capital’s Funds for Health Improvement and Research SF202222175
Corresponding Author Wei Sun, MD, Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. sunwei2134@163.com
Key Words Hepatocellular carcinoma; Lenvatinib; Immune checkpoint inhibitors; C-reactive protein; Alpha-fetoprotein
Core Tip The CRAFITY score, integrating baseline alpha-fetoprotein and C-reactive protein levels, has been limitedly investigated in patients receiving lenvatinib and programmed cell death protein 1 (PD-1) inhibitors. This study found significant differences in progression-free survival and overall survival across CRAFITY score strata in patients treated with lenvatinib and PD-1 inhibitors. Lower CRAFITY scores were associated with better objective response rates and disease control rates. These findings suggest that the CRAFITY score is a promising predictive tool for treatment response and survival in patients with unresectable hepatocellular carcinoma receiving lenvatinib and PD-1 inhibitors.
Publish Date 2025-01-20 07:38
Citation

Yin X, Deng N, Ding XY, Chen JL, Sun W. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. World J Gastroenterol 2025; 31(7): 101672

URL https://www.wjgnet.com/1007-9327/full/v31/i7/101672.htm
DOI https://dx.doi.org/10.3748/wjg.v31.i7.101672
Full Article (PDF) WJG-31-101672-with-cover.pdf